Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to -$5.0 million.

  • Legend Biotech's Capital Expenditures fell 14237.29% to -$5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 6015.52%. This contributed to the annual value of $14.1 million for FY2024, which is 2977.0% down from last year.
  • As of Q3 2025, Legend Biotech's Capital Expenditures stood at -$5.0 million, which was down 14237.29% from -$9.2 million recorded in Q2 2025.
  • Legend Biotech's Capital Expenditures' 5-year high stood at $35.8 million during Q4 2023, with a 5-year trough of -$42.2 million in Q4 2021.
  • In the last 5 years, Legend Biotech's Capital Expenditures had a median value of -$5.4 million in 2023 and averaged -$5.3 million.
  • Within the past 5 years, the most significant YoY rise in Legend Biotech's Capital Expenditures was 27118.08% (2023), while the steepest drop was 199068.32% (2023).
  • Quarter analysis of 5 years shows Legend Biotech's Capital Expenditures stood at -$42.2 million in 2021, then soared by 50.41% to -$20.9 million in 2022, then surged by 271.18% to $35.8 million in 2023, then dropped by 27.89% to $25.8 million in 2024, then plummeted by 119.38% to -$5.0 million in 2025.
  • Its Capital Expenditures stands at -$5.0 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$2.0 million for Q1 2025.